TY - JOUR T1 - Evolving strategies to reduce colectomy rates in primary sclerosing cholangitis-inflammatory bowel disease: clinical remission of corticosteroid refractory colitis post-liver transplant with vedolizumab JF - Frontline Gastroenterology JO - Frontline Gastroenterol SP - 271 LP - 274 DO - 10.1136/flgastro-2016-100711 VL - 7 IS - 4 AU - Saqib Mumtaz AU - Jason Goh AU - Gideon M Hirschfield AU - James Ferguson AU - Sheldon C Cooper Y1 - 2016/10/01 UR - http://fg.bmj.com/content/7/4/271.abstract N2 - Primary sclerosing cholangitis (PSC) is associated with inflammatory bowel disease (IBD) in approximately 70% of patients, with ulcerative colitis (UC) being the most common subtype of IBD identified. There is a paucity of data on the optimum management strategy for IBD flares in the post-liver transplant patient, particularly when refractory to conventional treatments. Vedolizumab is a novel gut-specific monoclonal antibody, which has recently been approved for use by National Institute for Health and Care Excellence for moderate-to-severe UC. We present an exemplar case of successful use of vedolizumab in the management of corticosteroid refractory PSC-IBD after liver transplantation. ER -